INIFY Laboratories AB (INIFY.OL) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Norway

Price
5.73 NOK
Market cap
616.13 m NOK
P/E (2025)
–
P/S (2025)
28.00
Dividend yield
0.00 %
Net margin
-308.49 %
Return on equity (ROE)
-63.72 %
Return on assets (ROA)
-48.30 %

INIFY Laboratories AB financials

Fiscal year20242025
Revenue13.13 m SEK22.01 m SEK
Gross profit11.25 m SEK18.60 m SEK
Operating income-52.99 m SEK-69.66 m SEK
EBIT-51.50 m SEK-67.81 m SEK
Net income-51.64 m SEK-67.89 m SEK
Diluted EPS – continuing operations-1.12 SEK-0.85 SEK

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About INIFY Laboratories AB

INIFY Laboratories AB provides cancer diagnostics services in Sweden. It offers prostate cancer diagnostics services. The company was incorporated in 2021 and is based in Stockholm, Sweden.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.